Rivalry Among Existing Competitors

Moderate rivalry persists in medical device/healthcare tech, with NYAX still trading at a premium valuation (EV/Sales TTM 4.38x, P/S 4.26x) that implies continued pressure to defend growth and margins.

Profitability remains thin, with net margin at 1.79% and operating margin at 4.26%, limiting pricing flexibility versus larger competitors.

Threat Of New Entrants

High switching and regulatory barriers remain supportive, as NYAX operates in a specialized healthcare technology niche with meaningful compliance and integration hurdles.

The balance sheet is still reasonably liquid (current ratio 2.12x, quick ratio 2.03x), which helps sustain investment in product and customer support against smaller entrants.

Bargaining Power Of Suppliers

Supplier power remains manageable, but interest burden is elevated and debt service coverage is only moderate, which can constrain flexibility if input or financing costs rise.

Capital intensity appears contained, with capex at 1.71% of revenue and capex/operating cash flow at 21.2%, reducing dependence on heavy external supplier investment.

Bargaining Power Of Buyers

Buyer power remains meaningful because customers can pressure pricing in a competitive healthcare procurement environment, while NYAX's low net margin leaves limited room for concessions.

Working capital metrics are acceptable but not strong enough to offset customer leverage, with days sales outstanding at 90.6 days and cash conversion cycle at 94.5 days.

Threat Of Substitutes

Substitution risk remains moderate because alternative healthcare workflow and payment solutions can compete on cost and integration, especially if NYAX cannot widen its margin profile.

The company's modest return on capital employed (3.20%) suggests it has not yet built a strong economic moat that would sharply reduce substitution pressure.

Overall Score